pDONR223-PRKD2 Citations (3)

Originally described in: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA Nature. 2010 Dec 16;468(7326):968-72. doi: 10.1038/nature09627 PubMed Journal

---

Articles Citing pDONR223-PRKD2

Articles
HSP90 supports tumor growth and angiogenesis through PRKD2 protein stabilization. Azoitei N, Diepold K, Brunner C, Rouhi A, Genze F, Becher A, Kestler H, van Lint J, Chiosis G, Koren J 3rd, Frohling S, Scholl C, Seufferlein T. Cancer Res. 2014 Dec 1;74(23):7125-36. doi: 10.1158/0008-5472.CAN-14-1017. Epub 2014 Oct 8. PubMed
Physical plasma-triggered ROS induces tumor cell death upon cleavage of HSP90 chaperone. Bekeschus S, Lippert M, Diepold K, Chiosis G, Seufferlein T, Azoitei N. Sci Rep. 2019 Mar 11;9(1):4112. doi: 10.1038/s41598-019-38580-0. PubMed
Sildenafil triggers tumor lethality through altered expression of HSP90 and degradation of PKD2. Chen L, Liu Y, Becher A, Diepold K, Schmid E, Fehn A, Brunner C, Rouhi A, Chiosis G, Cronauer M, Seufferlein T, Azoitei N. Carcinogenesis. 2020 Jan 9. pii: 5698682. doi: 10.1093/carcin/bgaa001. PubMed

If you have published an article using this material, please email us at to have your article added to this page.